Neurocrine Biosciences (NBIX) Quick Ratio: History & Chart

Neurocrine Biosciences, Inc.(NBIX)

Biotechnology · San Diego, CA

$145.51+1.30 (+0.90%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

San Diego, CA

2,500 employees

www.neurocrine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kyle W. Gano

View full financials

NBIX Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

1.75

QUICK RATIO (ACID-TEST) AVG TTM

2.86

QUICK RATIO (ACID-TEST) AVG 3Y

2.97

QUICK RATIO (ACID-TEST) AVG 5Y

3.24

QUICK RATIO (ACID-TEST) AVG 10Y

5.42

QUICK RATIO (ACID-TEST) AVG 15Y

7.65

QUICK RATIO (ACID-TEST) AVG 20Y

6.85

CURRENT VS TTM AVG

-38.60%

CURRENT VS 3Y AVG

-41.03%

CURRENT VS 5Y AVG

-45.90%

CURRENT VS 10Y AVG

-67.65%

CURRENT VS 15Y AVG

-77.07%

CURRENT VS 20Y AVG

-74.42%

SECTOR MEDIAN · HEALTHCARE

3.35

median of 870 covered companies

CURRENT VS SECTOR MEDIAN

-47.74%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Neurocrine Biosciences, Inc. (NBIX)	$14.63B	1.75	2.86	2.97	3.24
Exelixis, Inc. (EXEL)vs ›	$14.66B	3.38	3.54	3.46	4.12
Charles River Laboratories International, Inc. (CRL)vs ›	$14.69B	1.04	1.07	1.10	1.11
Jazz Pharmaceuticals plc (JAZZ)vs ›	$14.54B	1.58	2.83	2.38	2.61
Solventum Corporation (SOLV)vs ›	$15.07B	0.74	0.86	0.93	0.94
Ascendis Pharma A/S (ASND)vs ›	$14.04B	2.32	0.80	0.84	4.11
Summit Therapeutics Inc. (SMMT)vs ›	$13.81B	6.96	10.01	11.56	9.08
BridgeBio Pharma, Inc. (BBIO)vs ›	$13.11B	1.17	3.59	3.76	4.72
Halozyme Therapeutics, Inc. (HALO)vs ›	$13.01B	2.31	5.22	5.21	4.91
Corcept Therapeutics Incorporated (CORT)vs ›	$12.93B	2.77	3.05	4.30	5.45

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Neurocrine Biosciences, Inc. (NBIX)

$14.63B

1.75

2.86

2.97

3.24

Exelixis, Inc. (EXEL)vs ›

$14.66B

3.38

3.54

3.46

4.12

Charles River Laboratories International, Inc. (CRL)vs ›

$14.69B

1.04

1.07

1.10

1.11

Jazz Pharmaceuticals plc (JAZZ)vs ›

$14.54B

1.58

2.83

2.38

2.61

Solventum Corporation (SOLV)vs ›

$15.07B

0.74

0.86

0.93

0.94

Ascendis Pharma A/S (ASND)vs ›

$14.04B

2.32

0.80

0.84

4.11

Summit Therapeutics Inc. (SMMT)vs ›

$13.81B

6.96

10.01

11.56

9.08

BridgeBio Pharma, Inc. (BBIO)vs ›

$13.11B

1.17

3.59

3.76

4.72

Halozyme Therapeutics, Inc. (HALO)vs ›

$13.01B

2.31

5.22

5.21

4.91

Corcept Therapeutics Incorporated (CORT)vs ›

$12.93B

2.77

3.05

4.30

5.45

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The quick ratio (acid-test) for NBIX stock is 1.75.

Is Neurocrine Biosciences, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 1.75 is 46% below its 5-year average of 3.24, near the low end of its 5-year range (1.75–5.08).

What is the TTM average quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The TTM average quick ratio (acid-test) for NBIX stock is 2.86.

What is the 3Y average quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The 3Y average quick ratio (acid-test) for NBIX stock is 2.97.

What is the 5Y average quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The 5Y average quick ratio (acid-test) for NBIX stock is 3.24.

What is the 10Y average quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The 10Y average quick ratio (acid-test) for NBIX stock is 5.42.

What is the 15Y average quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The 15Y average quick ratio (acid-test) for NBIX stock is 7.65.

What is the 20Y average quick ratio (acid-test) for Neurocrine Biosciences, Inc. (NBIX)?

The 20Y average quick ratio (acid-test) for NBIX stock is 6.85.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	1.75
2026-03-31	2.85
2025-12-31	3.30
2025-09-30	3.27
2025-06-30	3.10
2025-03-31	3.02
2024-12-31	3.28
2024-09-30	4.26
2024-06-30	4.08
2024-03-31	2.47
2023-12-31	2.40
2023-09-30	2.34
2023-06-30	2.51
2023-03-31	3.74
2022-12-31	2.64
2022-09-30	2.41
2022-06-30	3.47
2022-03-31	3.90
2021-12-31	3.83
2021-09-30	4.34
2021-06-30	5.08
2021-03-31	5.55
2020-12-31	5.30
2020-09-30	1.86
2020-06-30	1.96
2020-03-31	6.75
2019-12-31	1.44
2019-09-30	6.99
2019-06-30	7.32
2019-03-31	8.61
2018-12-31	8.24
2018-09-30	1.55
2018-06-30	9.19
2018-03-31	11.06
2017-12-31	10.18
2017-09-30	14.37
2017-06-30	19.36
2017-03-31	10.16
2016-12-31	10.21
2016-09-30	13.42
2016-06-30	14.57
2016-03-31	17.23
2015-12-31	14.94
2015-09-30	19.31
2015-06-30	22.19
2015-03-31	26.66
2014-12-31	12.65
2014-09-30	13.09
2014-06-30	16.39
2014-03-31	20.90
2013-12-31	12.69
2013-09-30	11.95
2013-06-30	10.69
2013-03-31	11.56
2012-12-31	12.10
2012-09-30	7.70
2012-06-30	6.22
2012-03-31	5.05
2011-12-31	2.81
2011-09-30	2.81
2011-06-30	2.40
2011-03-31	2.58
2010-12-31	2.52
2010-09-30	2.47
2010-06-30	2.76
2010-03-31	3.67
2009-12-31	2.77
2009-09-30	2.42
2009-06-30	1.63
2009-03-31	2.07
2008-12-31	3.12
2008-09-30	5.21
2008-06-30	5.83
2008-03-31	8.47
2007-12-31	6.12
2007-09-30	6.40
2007-06-30	7.95
2007-03-31	9.56
2006-12-31	9.63
2006-09-30	9.63
2006-06-30	10.05
2006-03-31	8.39
2005-12-31	8.29
2005-09-30	8.49
2005-06-30	6.74
2005-03-31	5.96
2004-12-31	5.27
2004-09-30	4.67
2004-06-30	4.98
2004-03-31	3.91
2003-12-31	4.29
2003-09-30	4.03
2003-06-30	3.09
2003-03-31	3.52
2002-12-31	7.64
2002-09-30	9.49

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

1.75

2026-03-31

2.85

2025-12-31

3.30

2025-09-30

3.27

2025-06-30

3.10

2025-03-31

3.02

2024-12-31

3.28

2024-09-30

4.26

2024-06-30

4.08

2024-03-31

2.47

2023-12-31

2.40

2023-09-30

2.34

2023-06-30

2.51

2023-03-31

3.74

2022-12-31

2.64

2022-09-30

2.41

2022-06-30

3.47

2022-03-31

3.90

2021-12-31

3.83

2021-09-30

4.34

2021-06-30

5.08

2021-03-31

5.55

2020-12-31

5.30

2020-09-30

1.86

2020-06-30

1.96

2020-03-31

6.75

2019-12-31

1.44

2019-09-30

6.99

2019-06-30

7.32

2019-03-31

8.61

2018-12-31

8.24

2018-09-30

1.55

2018-06-30

9.19

2018-03-31

11.06

2017-12-31

10.18

2017-09-30

14.37

2017-06-30

19.36

2017-03-31

10.16

2016-12-31

10.21

2016-09-30

13.42

2016-06-30

14.57

2016-03-31

17.23

2015-12-31

14.94

2015-09-30

19.31

2015-06-30

22.19

2015-03-31

26.66

2014-12-31

12.65

2014-09-30

13.09

2014-06-30

16.39

2014-03-31

20.90

2013-12-31

12.69

2013-09-30

11.95

2013-06-30

10.69

2013-03-31

11.56

2012-12-31

12.10

2012-09-30

7.70

2012-06-30

6.22

2012-03-31

5.05

2011-12-31

2.81

2011-09-30

2.81

2011-06-30

2.40

2011-03-31

2.58

2010-12-31

2.52

2010-09-30

2.47

2010-06-30

2.76

2010-03-31

3.67

2009-12-31

2.77

2009-09-30

2.42

2009-06-30

1.63

2009-03-31

2.07

2008-12-31

3.12

2008-09-30

5.21

2008-06-30

5.83

2008-03-31

8.47

2007-12-31

6.12

2007-09-30

6.40

2007-06-30

7.95

2007-03-31

9.56

2006-12-31

9.63

2006-09-30

9.63

2006-06-30

10.05

2006-03-31

8.39

2005-12-31

8.29

2005-09-30

8.49

2005-06-30

6.74

2005-03-31

5.96

2004-12-31

5.27

2004-09-30

4.67

2004-06-30

4.98

2004-03-31

3.91

2003-12-31

4.29

2003-09-30

4.03

2003-06-30

3.09

2003-03-31

3.52

2002-12-31

7.64

2002-09-30

9.49

Quick Ratio (Acid-Test): 1.75

NBIX Quick Ratio

NBIX Average Quick Ratio (Acid-Test) Chart

NBIX Current vs Average Quick Ratio (Acid-Test) Chart

NBIX Quick Ratio (Acid-Test) Metrics

NBIX Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

NBIX Quick Ratio (Acid-Test) History

Related Metrics